Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1996 Mar 15;97(6):1366–1372. doi: 10.1172/JCI118556

Low-density lipoprotein receptor-deficient mice are protected against lethal endotoxemia and severe gram-negative infections.

M G Netea 1, P N Demacker 1, B J Kullberg 1, O C Boerman 1, I Verschueren 1, A F Stalenhoef 1, J W van der Meer 1
PMCID: PMC507194  PMID: 8617867

Abstract

Lipoproteins can bind lipopolysaccharide (LPS) and decrease the LPS-stimulated production of pro-inflammatory cytokines. We investigated the effect of increased plasma concentrations of low-density-lipoproteins (LDL) on survival and cytokine production after a lethal challenge with either LPS or live Gram-negative bacteria in LDL receptor deficient mice (LDLR-/-). The LDLR-/- mice challenged with LPS had an eightfold increased LD50 when compared with the wild type controls (C57Bl/6J), while tumor necrosis factor alpha (TNFalpha) and interleukin-1 alpha (IL-1 alpha) plasma concentrations were decreased twofold. LDLR-/- mice had significantly lower and delayed mortality than control mice after infection with Klebsiella pneumoniae. No differences in the outgrowth of bacteria in the organs were present between the two groups, while circulating cytokine concentrations were decreased twofold in LDLR-/- mice. In contrast, the LPS-stimulated in vitro production of cytokines by peritoneal macrophages of LDLR-/- mice was significantly increased compared with controls. This increase was associated with enhanced specific binding of LPS to the macrophages of LDLR-/- mice. In conclusion, endogenous LDL can protect against the lethal effects of endotoxin and Gram-negative infection. At least part of this protection is achieved through decreased in vivo production of pro-inflammatory cytokines, in spite of increased cytokine production capacity.

Full Text

The Full Text of this article is available as a PDF (201.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ashkenazi A., Marsters S. A., Capon D. J., Chamow S. M., Figari I. S., Pennica D., Goeddel D. V., Palladino M. A., Smith D. H. Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin. Proc Natl Acad Sci U S A. 1991 Dec 1;88(23):10535–10539. doi: 10.1073/pnas.88.23.10535. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bazil V., Strominger J. L. Shedding as a mechanism of down-modulation of CD14 on stimulated human monocytes. J Immunol. 1991 Sep 1;147(5):1567–1574. [PubMed] [Google Scholar]
  3. Beutler B., Milsark I. W., Cerami A. C. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science. 1985 Aug 30;229(4716):869–871. doi: 10.1126/science.3895437. [DOI] [PubMed] [Google Scholar]
  4. Cavaillon J. M., Fitting C., Haeffner-Cavaillon N., Kirsch S. J., Warren H. S. Cytokine response by monocytes and macrophages to free and lipoprotein-bound lipopolysaccharide. Infect Immun. 1990 Jul;58(7):2375–2382. doi: 10.1128/iai.58.7.2375-2382.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Eggesbø J. B., Hjermann I., Lund P. K., Joø G. B., Ovstebø R., Kierulf P. LPS-induced release of IL-1 beta, IL-6, IL-8, TNF-alpha and sCD14 in whole blood and PBMC from persons with high or low levels of HDL-lipoprotein. Cytokine. 1994 Sep;6(5):521–529. doi: 10.1016/1043-4666(94)90080-9. [DOI] [PubMed] [Google Scholar]
  6. Eichbaum E. B., Harris H. W., Kane J. P., Rapp J. H. Chylomicrons can inhibit endotoxin activity in vitro. J Surg Res. 1991 Nov;51(5):413–416. doi: 10.1016/0022-4804(91)90143-a. [DOI] [PubMed] [Google Scholar]
  7. Esfahani M., Bigler R. D., Alfieri J. L., Lund-Katz S., Baum J. D., Scerbo L. Cholesterol regulates the cell surface expression of glycophospholipid-anchored CD14 antigen on human monocytes. Biochim Biophys Acta. 1993 Jul 4;1149(2):217–223. doi: 10.1016/0005-2736(93)90204-d. [DOI] [PubMed] [Google Scholar]
  8. Feingold K. R., Funk J. L., Moser A. H., Shigenaga J. K., Rapp J. H., Grunfeld C. Role for circulating lipoproteins in protection from endotoxin toxicity. Infect Immun. 1995 May;63(5):2041–2046. doi: 10.1128/iai.63.5.2041-2046.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Flegel W. A., Wölpl A., Männel D. N., Northoff H. Inhibition of endotoxin-induced activation of human monocytes by human lipoproteins. Infect Immun. 1989 Jul;57(7):2237–2245. doi: 10.1128/iai.57.7.2237-2245.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Harris H. W., Grunfeld C., Feingold K. R., Rapp J. H. Human very low density lipoproteins and chylomicrons can protect against endotoxin-induced death in mice. J Clin Invest. 1990 Sep;86(3):696–702. doi: 10.1172/JCI114765. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Harris H. W., Grunfeld C., Feingold K. R., Read T. E., Kane J. P., Jones A. L., Eichbaum E. B., Bland G. F., Rapp J. H. Chylomicrons alter the fate of endotoxin, decreasing tumor necrosis factor release and preventing death. J Clin Invest. 1993 Mar;91(3):1028–1034. doi: 10.1172/JCI116259. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hubsch A. P., Powell F. S., Lerch P. G., Doran J. E. A reconstituted, apolipoprotein A-I containing lipoprotein reduces tumor necrosis factor release and attenuates shock in endotoxemic rabbits. Circ Shock. 1993 May;40(1):14–23. [PubMed] [Google Scholar]
  13. Ishibashi S., Brown M. S., Goldstein J. L., Gerard R. D., Hammer R. E., Herz J. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest. 1993 Aug;92(2):883–893. doi: 10.1172/JCI116663. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Leirisalo-Repo M., Jättelä M., Gylling H., Miettinen T. A., Repo H. Phagocyte function in familial hypercholesterolaemia: peripheral blood monocytes exposed to lipopolysaccharide show increased tumour necrosis factor production. Scand J Immunol. 1990 Dec;32(6):679–685. doi: 10.1111/j.1365-3083.1990.tb03210.x. [DOI] [PubMed] [Google Scholar]
  15. Levine D. M., Parker T. S., Donnelly T. M., Walsh A., Rubin A. L. In vivo protection against endotoxin by plasma high density lipoprotein. Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):12040–12044. doi: 10.1073/pnas.90.24.12040. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Lynn W. A., Cohen J. Adjunctive therapy for septic shock: a review of experimental approaches. Clin Infect Dis. 1995 Jan;20(1):143–158. doi: 10.1093/clinids/20.1.143. [DOI] [PubMed] [Google Scholar]
  17. Mathison J., Tobias P., Wolfson E., Ulevitch R. Regulatory mechanisms of host responsiveness to endotoxin (lipopolysaccharide). Pathobiology. 1991;59(3):185–188. doi: 10.1159/000163641. [DOI] [PubMed] [Google Scholar]
  18. Munford R. S., Andersen J. M., Dietschy J. M. Sites of tissue binding and uptake in vivo of bacterial lipopolysaccharide-high density lipoprotein complexes: studies in the rat and squirrel monkey. J Clin Invest. 1981 Dec;68(6):1503–1513. doi: 10.1172/JCI110404. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Netea M. G., Blok W. L., Kullberg B. J., Bemelmans M., Vogels M. T., Buurman W. A., van der Meer J. W. Pharmacologic inhibitors of tumor necrosis factor production exert differential effects in lethal endotoxemia and in infection with live microorganisms in mice. J Infect Dis. 1995 Feb;171(2):393–399. doi: 10.1093/infdis/171.2.393. [DOI] [PubMed] [Google Scholar]
  20. Peto R., Pike M. C., Armitage P., Breslow N. E., Cox D. R., Howard S. V., Mantel N., McPherson K., Peto J., Smith P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977 Jan;35(1):1–39. doi: 10.1038/bjc.1977.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Pugin J., Schürer-Maly C. C., Leturcq D., Moriarty A., Ulevitch R. J., Tobias P. S. Lipopolysaccharide activation of human endothelial and epithelial cells is mediated by lipopolysaccharide-binding protein and soluble CD14. Proc Natl Acad Sci U S A. 1993 Apr 1;90(7):2744–2748. doi: 10.1073/pnas.90.7.2744. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Read T. E., Grunfeld C., Kumwenda Z. L., Calhoun M. C., Kane J. P., Feingold K. R., Rapp J. H. Triglyceride-rich lipoproteins prevent septic death in rats. J Exp Med. 1995 Jul 1;182(1):267–272. doi: 10.1084/jem.182.1.267. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Rothberg K. G., Ying Y. S., Kamen B. A., Anderson R. G. Cholesterol controls the clustering of the glycophospholipid-anchored membrane receptor for 5-methyltetrahydrofolate. J Cell Biol. 1990 Dec;111(6 Pt 2):2931–2938. doi: 10.1083/jcb.111.6.2931. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Tahri-Jouti M. A., Chaby R. Binding of endotoxin to macrophages: distinct effects of serum constituents. Immunol Invest. 1991 Jul;20(4):377–386. doi: 10.3109/08820139109057763. [DOI] [PubMed] [Google Scholar]
  25. Tracey K. J., Fong Y., Hesse D. G., Manogue K. R., Lee A. T., Kuo G. C., Lowry S. F., Cerami A. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature. 1987 Dec 17;330(6149):662–664. doi: 10.1038/330662a0. [DOI] [PubMed] [Google Scholar]
  26. Ulevitch R. J., Johnston A. R. The modification of biophysical and endotoxic properties of bacterial lipopolysaccharides by serum. J Clin Invest. 1978 Dec;62(6):1313–1324. doi: 10.1172/JCI109252. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Van Lenten B. J., Fogelman A. M., Haberland M. E., Edwards P. A. The role of lipoproteins and receptor-mediated endocytosis in the transport of bacterial lipopolysaccharide. Proc Natl Acad Sci U S A. 1986 Apr;83(8):2704–2708. doi: 10.1073/pnas.83.8.2704. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Vogels M. T., Mensink E. J., Ye K., Boerman O. C., Verschueren C. M., Dinarello C. A., van der Meer J. W. Differential gene expression for IL-1 receptor antagonist, IL-1, and TNF receptors and IL-1 and TNF synthesis may explain IL-1-induced resistance to infection. J Immunol. 1994 Dec 15;153(12):5772–5780. [PubMed] [Google Scholar]
  29. Wakabayashi G., Gelfand J. A., Burke J. F., Thompson R. C., Dinarello C. A. A specific receptor antagonist for interleukin 1 prevents Escherichia coli-induced shock in rabbits. FASEB J. 1991 Mar 1;5(3):338–343. doi: 10.1096/fasebj.5.3.1825816. [DOI] [PubMed] [Google Scholar]
  30. Warren H. S., Riveau G. R., de Deckker F. A., Chedid L. A. Control of endotoxin activity and interleukin-1 production through regulation of lipopolysaccharide-lipoprotein binding by a macrophage factor. Infect Immun. 1988 Jan;56(1):204–212. doi: 10.1128/iai.56.1.204-212.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Watson J., Riblet R. Genetic control of responses to bacterial lipopolysaccharides in mice. II. A gene that influences a membrane component involved in the activation of bone marrow-derived lymphocytes by lipipolysaccharides. J Immunol. 1975 May;114(5):1462–1468. [PubMed] [Google Scholar]
  32. Wurfel M. M., Hailman E., Wright S. D. Soluble CD14 acts as a shuttle in the neutralization of lipopolysaccharide (LPS) by LPS-binding protein and reconstituted high density lipoprotein. J Exp Med. 1995 May 1;181(5):1743–1754. doi: 10.1084/jem.181.5.1743. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Wurfel M. M., Kunitake S. T., Lichenstein H., Kane J. P., Wright S. D. Lipopolysaccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS. J Exp Med. 1994 Sep 1;180(3):1025–1035. doi: 10.1084/jem.180.3.1025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. van der Meer J. W., Barza M., Wolff S. M., Dinarello C. A. A low dose of recombinant interleukin 1 protects granulocytopenic mice from lethal gram-negative infection. Proc Natl Acad Sci U S A. 1988 Mar;85(5):1620–1623. doi: 10.1073/pnas.85.5.1620. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. van der Meer J. W. The effects of recombinant interleukin-1 and recombinant tumor necrosis factor on non-specific resistance to infection. Biotherapy. 1988;1(1):19–25. doi: 10.1007/BF02170132. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES